Compare Acadia Healthcare Company Inc (ACHC) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Acadia Healthcare Company Inc vs Recursion Pharmaceuticals Inc — how do they compare? Acadia Healthcare Company Inc trades at $30.77 (market cap $2.94B), while Recursion Pharmaceuticals Inc trades at $3.71 (market cap $2.04B). The key difference: Acadia Healthcare Company Inc is the larger of the two by market cap, and Acadia Healthcare Company Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| ACHC | RXRX | |
|---|---|---|
Market Cap | $2.94B | $2.04B |
Sector | Health | Health |
52-Week High | $31.92 | $6.79 |
52-Week Low | $11.68 | $2.84 |
Enterprise Value | $5.45B | $1.46B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACHC trades at $31.09, down 2.57% today but maintains a bullish technical outlook with strong moving average support. The company shows operational strength with three consecutive earnings beats, though profitability remains challenged with a -32.84% net margin. Analyst consensus is strongly bullish with 68% buy ratings, while recent news highlights the company's strategic shift toward profitability and rising behavioral health demand.
The stock presents a mixed opportunity with strong technical momentum and analyst support offset by persistent profitability challenges. Key catalysts include continued earnings outperformance and successful execution of the turnaround strategy, while risks center on margin pressures and high short interest that could limit upside potential.
RXRX trades at $3.96, up 4.21% today, with a bullish technical signal from moving averages despite overbought RSI readings. The company shows improving quarterly EPS beats but faces deep losses with a -851.51% net margin. Recent news highlights its AI-driven drug discovery platform and inclusion in Cathie Wood's portfolio (The Motley Fool, 2026-07-05).
Analyst consensus is mixed with 40% buy ratings and a $7.83 price target suggesting significant upside, but high cash burn and negative profitability pose substantial risks. Investment appeal hinges on successful clinical advancements offsetting current financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Acadia Healthcare Company Inc
Acadia Healthcare is a leading provider of behavioral healthcare services across the US and Puerto Rico. It operates a network of psychiatric hospitals, residential treatment centers, and clinics for mental health and addiction recovery.
Read more on ACHC →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
